Based on the KRAS mutation-derived estimates of tumor cellularity, roughly 14 of the 24 samples would be suitable for whole-exome sequencing, and only 3 of the samples would be ideal for whole-genome sequencing. The gene discussed is KRAS; the disease is neoplasm.